Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 3/20 | 0.58 |
| ▸ | TTR | P02766 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919649 | 1.00 | AHR (0.67) | AHRLCKTTRKDM4ELMNA | |
| SCHEMBL20657984 | 0.85 | AHR (0.69) | AHRLCKTTRKDM4ELMNA | |
| SCHEMBL918909 | 0.84 | AHR (0.73) | AHRLCKTTRKDM4ELMNA | |
| SCHEMBL918908 | 0.84 | AHR (0.73) | AHRLCKTTRKDM4ELMNA | |
| Tapinarof SCHEMBL918344 | 0.80 | AHR (1.00) | AHRTTRKDM4ETP53CYP3A4 | |
| Tapinarof SCHEMBL918343 | 0.80 | AHR (1.00) | AHRTTRKDM4ETP53CYP3A4 | |
| SCHEMBL919556 | 0.80 | AHR (0.62) | AHRLCKTTRKDM4ELMNA | |
| SCHEMBL20657985 | 0.80 | AHR (0.68) | AHRLCKTTRKDM4ELMNA | |
| SCHEMBL919558 | 0.80 | AHR (0.62) | AHRLCKTTRKDM4ELMNA | |
| Tapinarof SCHEMBL28021456 | 0.80 | AHR (1.00) | AHRTTRKDM4ETP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080255245-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-7321050-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2008-01-22 | — | — | US | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | AHR 1108/4885LCK 69/4885TTR 3947/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | AHR 1542/4885LCK 21/4885TTR 3052/4885 |
| US-20080255245-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues | NFKBIA, IKBKB, IKBKE | AHR 1017/4885LCK 76/4885TTR 4152/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | AHR 1326/4885LCK 86/4885TTR 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.